VOLITIONRX LTD — Director's Dealing 2022

Jun 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-06-23-05:00

Reporting Person: Forterre Gael (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-23-05:00	Common Stock	A	13308	—	Acquired	68973	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-23-05:00	Stock Option (Right to Buy)	$3.40	A	24524	Acquired	2031-08-03-05:00	Common Stock (24524)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Indirect
Common Stock	32500	Indirect

Footnotes

F1: On August 3, 2021, the reporting person was awarded 20,473 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,308 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 6,655 units and 6,653 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,165 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

F2: These shares of common stock are managed by Armori Capital Management, LLC ("Armori Capital"). Mr. Forterre is the managing director and sole shareholder of Armori Capital and has voting and dispositive control over the shares held by Armori Capital. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,524 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,262 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 13,204 shares subject to the award previously vested and remain subject to time-based vesting.